Corrélations des profils TEP au 18F-FDG,IRM et clinico-biologiques des encéphalites dysimmunitaires

IntroductionDysimmune encephalitis (DE) are rare and serious diseases. Their diagnosis is based on a set of arguments, in absence of gold standard. The discovery of anti-neuronal antibodies, although specific, is inconstant. FDG PET has a high sensitivity in this indication. Accordingly, its place is increasing in the diagnosis and monitoring of DE. We looked for associations between different patterns found in ¹⁸FDG PET in ED, and different data from the medical file, including biology, MRI, and EEG.Material and methodsWe collected retrospectively the medical records data of 30 patients of the Marseille La Timone hospital, having had a diagnosis of DE, and benefited from both a ¹⁸FDG cerebral PET/CT and a lumbar puncture in a time lapse of maximum of 15 days, from January 2010 to September 2015.ResultsThe statistical analysis showed significant associations between brain hypermetabolism and intrathecal synthesis. The second interesting finding concerned brain hypometabolism, which was significantly associated with more serious conditions, both paraclinically, with MRI more often pathological, and antibodies identified in CSF more frequently, and clinically. It also proved that the patterns of cerebral ¹⁸FDG PET, although pathological, most often varied widely, and no specific pattern was found.DiscussionFuture research will determine if there are associations between cerebral ¹⁸FDG PET findings, and prognostic factors, particularly in terms of therapeutic response in the DE.     

La TEP au 18F-FDG dans la pathologie inflammatoire et infectieuse : intestinale,prothétique,fibrose, sarcoïdose,tuberculose…

Nuclear medicine plays an important role in the evaluation of infection and inflammation. A variety of diagnostic methods are available for imaging this inflammation and infection, most notably computed tomography, ⁶⁸Ga scintigraphy or radionuclide labeled leucocytes. Fluorine 18 fluorodeoxyglucose (¹⁸F-FDG) is a readily available radiotracer that offers rapid, exquisitely sensitive high-resolution images by positron emission tomography (PET).Inflammation can be acute or chronic, the former showing predominantly neutrophilic granulocyte infiltrates, whereas in the latter, macrophages predominate. FDG uptake in infection is based on the fact that mononuclear cells and granulocytes use large quantities of glucose by way of the hexose monophosphate shunts. ¹⁸F-FDG PET accurately helps diagnose spinal osteomyelitis, diabetic foot and in inflammatory conditions such as sarcoidosis and tuberculosis.(it appears to be useful for defining the extent of disease and monitoring response to treatment). ¹⁸F-FDG PET can also help localize the source of fever of undetermined origin, thereby guiding additional testing. ¹⁸F-FDG PET may be of limited usefulness in postoperative patients and in patients with a failed joint prosthesis or bowel inflammatory disease. In this review, we will focus on the role of ¹⁸F-FDG PET in the management of patients with inflammation or suspected or confirmed infection.     

Intérêt de la tomographie par émission de positons (TEP) au 18FDG dans le suivi des patients traités pour carcinome épidermoïde des voies aérodigestives supérieures (VADS) en rémission clinique

IntroductionPosttreatment follow-up of head and neck squamous cell carcinoma (HNSCC) recurrence is a diagnostic challenge. Tissue distortions from radiation and surgery can obscure early detection of recurrence by conventional follow-up approaches such as physical examination (PE), computed tomography, and magnetic resonance imaging. A number of studies have shown that ¹⁸Fluoro-fluorodeoxyglucose (¹⁸FDG) Positron emission tomography (PET) may be an effective technique for the detection of persistent, recurrent, and distant metastatic HNSCC after treatment. The aim of this prospective study was to determine the benefits (sensitivity, specificity, predictive values, and accuracy) of ¹⁸FDG PET using hybrid PET–Computed tomography system (PET/CT) in the detection of HNSCC subclinical locoregional recurrence and distant metastases, in patients 12 months after curative treatment with a negative conventional follow up.Materials and MethodsNinety-one patients cured from head and neck squamous cell carcinoma (HNSCC) without any clinical element for recurrence were included. Whole-body ¹⁸FDG PET/CT examination was performed 11.6 ± 4.4 months after the end of the treatment. The gold standard was histopathology or 6 months imaging follow-up.ResultsThe whole-body ¹⁸FDG PET/CT of the 91 patients in this study consisted of 52 negative and 39 positive results. Nine of these patients who exhibited abnormal ¹⁸FDG uptake in head and neck area did not have subsequently proven recurrent HNSCC (false positive). Thirty had proven recurrence (true positive). All 52 patients with negative readings of ¹⁸FDG PET/CT remained free of disease at 6 months (true negative). The sensitivity and specificity of ¹⁸FDG PET/CT in this study for the diagnosis of HNSCC recurrence were 100% (30/30) and 85% (52/61) respectively. The positive predictive value was 77% (30/39). The negative predictive value was 100% (52/52). The overall accuracy was 90% (82/91).ConclusionThe results of our study confirm the high effectiveness of ¹⁸FDG PET/CT in assessment of HNSCC recurrence. It suggests that this modality is more accurate than conventional follow-up PE alone in the assessment of patient recurrence after previous curative treatment for HNSCC. Therefore, a PET study could be systematically proposed at 12 months after the end of the treatment.     

Cancer de la prostate : utilité de la TEP-TDM à la F-fluorocholine

In oncology, positron emission computed tomography (PET/CT) has become an essential tool for initial staging, response evaluation and follow-up of cancer patients. Most of the frequent tumors (lung, breast, esophagus, and lymphomas) are highly avid for ¹⁸F-fluorodeoxyglucose (¹⁸FDG), but prostate cancer has not demonstrated significant uptake of FDG. The development of new tracers labeled with ¹⁸F such as choline analogs allowed already to obtain interesting results particularly in patients with biological relapse and inconclusive conventional imaging work-up. The impact of ¹⁸F-flurocholine PET/CT on patient management needs to be validated in large studies, but many centers use already this examination in order to guide further management, including radiotherapy planning.     

La fixation vasculaire du 18FDG est reliée au risque d’événements récents ou futurs chez les patients à haut risque cardiovasculaire

With this study, we sought to identify plaque inflammation as assessed by ¹⁸FDG uptake on positron emission tomography (PET)/computed tomography (CT) as an independent cardiovascular risk factor in patients at high risk for cardiovascular events. We compared 31 consecutive cancer patients presenting with visually enhanced ¹⁸FDG uptake in arterial walls on PET/CT (Group 1) to a selection of 34 matched cancer patients not showing arterial uptake (Group 2). All patients were followed for two years before and six months after PET/CT… Cardiovascular events were classified as older (>6 months before PET/CT) or recent (<6 months before or after PET/CT). ¹⁸FDG uptake was computed on non-attenuation corrected data by a AW/L ratio: mean Arterial Wall uptake/Lung uptake in a normal area, and by SUV on corrected data. A calcium score (CS) was also calculated. ¹⁸FDG uptake and CS were higher in Group 1 than Group 2 (both p = 0.02), and older and recent cardiovascular events were significantly more frequent in Group 1 than Group 2 (p = 0.001 and p = 0.03, respectively). Among the following parameters: number of conventional risk factor, calcium score and presence of ¹⁸FDG uptake, only the latter was significantly related to the occurrence of a recent event by multivariate analysis (p = 0.02). Patients with elevated arterial ¹⁸FDG uptake have a high risk of immediate or future cardiovascular events. Arterial ¹⁸FDG uptake is an indicator of evolving atherosclerotic process and can indicate future cardiovascular events.     

Thromboses néoplasiques et thromboses cruoriques mécaniques compliquant un cancer du testicule gauche en TEP/TDM au 18FDG

We report the case of a 46-year-old patient with pulmonary embolism complicating thrombosis of the left renal vein and inferior vena cava, which came from a malignant tumor of the left testicle. The case has been elucidated by positron emission tomography with ¹⁸FDG coupled to the CT-scan (PET/CT), performed as part of the etiological assessment of this pulmonary embolism, and anatomical and physiological considerations. The examination revealed ¹⁸FDG uptake in thrombus of the left kidney vein and the inferior vena cava. In view of the anatomy of the left spermatic vein, this finding led to the left testicle, which shows no nuclide uptake but was bathed in a large hydrocele visible on CT images. If several cases of pulmonary embolism or thrombosis of the inferior vena cava revealing a testicular cancer have been described in the literature, there has been no report including ¹⁸FDG PET/CT to the best of our knowledge. This case illustrates the imaging differences between bland and malignant thrombus as a consequence of their pathophysiology. It highlights the contribution of CT images from the PET/CT for the diagnosis.     

Use of 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography to Aid in Diagnosing Intestinal Adenocarcinoma in 2 Rhesus Macaques (Macaca mulatta)

Two aged female rhesus macaques (Macaca mulatta) presented with weight loss and intermittent inappetence. The signalment and constellation of clinical signs led clinicians to suspect the presence of intestinal adenocarcinoma. Because of each animal''s advanced age and inconclusive radiographic findings, a noninvasive diagnostic tool was preferred over exploratory laparotomy to assist in determining a diagnosis. Consequently, 2-[¹⁸F]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography–CT (FDG-PET–CT) was chosen to aid in confirming a suspicion of gastrointestinal adenocarcinoma in both animals. FDG is a glucose analogue labeled with fluorine-18 and is taken up by highly metabolically active cells, as observed in many cancers. Tomography revealed an annular constriction of the small intestine with focal FDG uptake in one animal, and an FDG avid transmural mass in the ascending colon of the second animal. Necropsy later confirmed both sites to be adenocarcinomas. This report supports the use of FDG-PET–CT as an adjunct to conventional radiography in the diagnosis of intestinal adenocarcinoma in nonhuman primates.Abbreviations: FDG, 2-[¹⁸F]fluoro-2-deoxy-d-glucose; PET, positron emission tomographyThe noninvasive imaging modality 2-[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography-computed tomography (FDG-PET–CT) is used primarily for the detection and staging of cancer and for the assessment of therapeutic response.²⁸ This modality also is useful for the identification of some infectious and inflammatory diseases, as demonstrated in the recent report of intense FDG uptake in a case of pneumonia in a miniature pig.¹⁴ Furthermore, FDG-PET–CT has been helpful in the detection and monitoring of inflammatory bowel disease and complicating infections of the gastrointestinal tract.²⁸PET detects the three-dimensional distribution of radioactivity based on the annihilation photons emitted by radiotracers labeled with positron-emitting radionuclides, such as ¹⁸F-labeled FDG. In this manner, PET enables noninvasive assessment of biochemical processes. In contrast, CT uses X-rays to generate high-resolution images, allowing clear visualization of anatomic structures. In PET–CT, both the multidetector CT apparatus and the PET detectors are mounted in the same scanner, one behind the other. The PET data are superimposed on the CT data (coregistration), enabling precise anatomic localization of FDG activity.²⁹ Combining PET imaging with CT allows the fusion of functional and anatomic information acquired almost simultaneously, facilitating the visualization and localization of metabolic information noninvasively.Intestinal adenocarcinoma is a substantial cause of morbidity and mortality in aged rhesus macaques.^25,26,30 Rhesus macaques often are maintained on long term-studies, resulting in a population of animals exhibiting morbidities associated with advanced age.^20,25,26 As the age of the animals in our care advances, so too must our diagnostic capabilities advance. Here we report the use of a noninvasive method, FDG-PET–CT, to support the diagnosis of intestinal adenocarcinoma in 2 aged rhesus macaques. We describe the physics of PET, biochemical rationale for the use of FDG, and pitfalls of interpretation.     

Place de la tomographie par émission de positons (TEP) au [18F]FDG dans l’exploration des vascularites

[¹⁸F]fluorodeoxyglucose (¹⁸FDG) positron emission tomography (PET) is a noninvasive metabolic imaging modality that is well suited to the assessment of activity and extent of large vessel vasculitis, such as giant cell arteritis and Takayasu arteritis. PET could be more effective than magnetic resonance imaging in detecting the earliest stages of vascular wall inflammation. The visual grading of vascular [¹⁸F]FDG uptake makes it possible to discriminate arteritis from atherosclerosis, providing therefore high specificity. High sensitivity can be achieved provided scanning is performed during active inflammatory phase, preferably before starting corticosteroid treatment. Large scale prospective studies are needed to determine the exact value of PET imaging in assessing the large vessel vasculitis outcome and response to immunosuppressive treatment.     

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

This study was aimed to investigate the significance of ¹⁸F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis (sHLH) patients. A total of 18 patients received ¹⁸F-FDG PET/CT scan at initial diagnosis. All patients (18/18) had at least 3 organs involved, with increased FDG metabolism in different degrees. Fifteen cases (15/18) had definite underlying diseases, including infections (IAHLH), rheumatosis (RAHLH), or malignancy (MAHLH). The SUV_max of patients in MAHLH group was significantly higher than patients in IAHLH group or RAHLH group (P?=?0.015, P?=?0.045). Furthermore, the SUV_max of patients in IAHLH group was significantly higher than patients of RAHLH group (P?=?0.043). Therefore, we concluded that ¹⁸F-FDG PET/CT may especially play important role in differential diagnosis of sHLH.     

The use of 2-[18F]fluoro-2-deoxy-d-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography

In this study, 2-[¹⁸F]fluoro-2-deoxy-d-glucose, ([¹⁸F]FDG) was used to radiolabel human granulocytes in vitro for possible clinical use by positron emission tomography (PET). Uptake of [¹⁸F]FDG was dependent on the amount of glucose in the labelling medium, e.g. when 1 × 10⁷ granulocytes were incubated with [¹⁸F]FDG containing 15μg/mL glucose 80% of [¹⁸F]FDG was incorporated within 30 min, but in the presence of 1 mg/mL of glucose it was reduced to 2%. Increasing the cell concentration and activating the granulocytes with Streptococcus pneumoniae, opsonized zymosan or phorbol myristate acetate all increased the uptake of [¹⁸F]FDG. Retention of the [¹⁸F]FDG by the cells as [¹⁸F]FDG-6-phosphate was also dependent on the extracellular glucose concentration, 9% was released within 60 min in the absence of glucose, but 27% in the presence of 1 mg/mL glucose.     

Quantification of 18FDG in the Normal Colon—A First Step in Investigating Whether Its Presence Is a Marker of a Physiological Process

The visibility of the colon in positron emission tomography (PET) scans of patients without gastrointestinal disease indicating the presence of ¹⁸F Fluorodeoxyglucose (¹⁸FDG) is well recognised, but unquantified and unexplained. In this paper a qualitative scoring system was applied to PET scans from 30 randomly selected patients without gastrointestinal disease to detect the presence of ¹⁸FDG in 4 different sections of the colon and then both the total pixel value and the pixel value per unit length of each section of the colon were determined to quantify the amount of ¹⁸FDG from a randomly selected subset of 10 of these patients. Analysis of the qualitative scores using a non-parametric ANOVA showed that all sections of the colon contained ¹⁸FDG but there were differences in the amount of ¹⁸FDG present between sections (p<0.05). Wilcoxon matched-pair signed-rank tests between pairs of segments showed statistically significant differences between all pairs (p<0.05) with the exception of the caecum and ascending colon and the descending colon. The same non-parametric statistical analysis of the quantitative measures showed no difference in the total amount of ¹⁸FDG between sections (p>0.05), but a difference in the amount/unit length between sections (p<0.01) with only the caecum and ascending colon and the descending colon having a statistically significant difference (p<0.05). These results are consistent since the eye is drawn to focal localisation of the ¹⁸FDG when qualitatively scoring the scans. The presence of ¹⁸FDG in the colon is counterintuitive since it must be passing from the blood to the lumen through the colonic wall. There is no active mechanism to achieve this and therefore we hypothesise that the transport is a passive process driven by the concentration gradient of ¹⁸FDG across the colonic wall. This hypothesis is consistent with the results obtained from the qualitative and quantitative measures analysed.     

Metformin May Be Associated with False-Negative Cancer Detection in the Gastrointestinal Tract on Pet/Ct

ObjectiveConcurrent therapy with the antihyperglycemic drug metformin can hinder the detection of malignancy in the abdominal and pelvic portions of ¹⁸F-fluordeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging performed for the diagnosis or staging of malignancy, as well as for treatment response and radiation therapy planning. This is due to the metformin-induced increase in intestinal FDG radiotracer uptake. We aim to bring this potentially important interaction to the attention of clinicians who care for cancer patients with diabetes.MethodsWe searched MEDLINE (from 1970 to January 2014)and Google Scholar for relevant English-language articles using the following search terms: “metformin and FDG/PET, metformin and bowel uptake, metformin, and cancer, metformin and the intestine, metformin pharmacokinetics, hyperglycemia and FDG/PET.” We reviewed the reference lists of pertinent articles with respect to metformin gut physiology, impact on FDG uptake and the effect on diagnostic accuracy of abdominal-pelvic PET/CT scans with concurrent metformin therapy.ResultsWe reviewed the action of metformin in the intestine, with particular emphasis on the role of metformin in PET/CT imaging and include a discussion of clinical studies on the topic to help refine knowledge and inform practice. Finally, we discuss aspects pertinent to the management of type 2 diabetes (T2D) patients on metformin undergoing PET/CT.ConclusionsMetformin leads to intense, diffusely increased FDG uptake in the colon, and to a lesser degree, the small intestine, which limits the diagnostic capabilities of FDG PET/CT scanning and may mask gastrointestinal malignancies. We suggest that metformin be discontinued 48 hours before FDG PET/CT scanning is performed in oncology patients. More rigorous data are needed to support the widespread generalizability of this recommendation. (Endocr Pract. 2014;20:1079-1083)     

Combination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate cancer

Aim of the studyIn this study, we aimed to determine the factors affecting increased glucose metabolism, which is one of the dedifferentiation mechanisms, by using [¹⁸F]FDG and [⁶⁸Ga]Ga-PSMA PET/CT in patients with castration-resistant prostate cancer (CRPC).Materials and methodNinety-three patients with CRPC were included in the study. Gleason score (GS), and total PSA and free PSA levels of the patients were recorded. Patient- and organ-based evaluations were performed according to the lesion uptakes as follows: score 0: PSMA (-) FDG (-), score 1: PSMA (+) FDG (-), score 2: PSMA (+) FDG (+) (FDG < PSMA), score 3: PSMA (+) FDG (+) (FDG = PSMA), score 4: PSMA (+) FDG (+) (FDG > PSMA), and score 5: PSMA (-) FDG (+). scores 1 and 2 were classified as group 1, and scores 3 to 5 were classified as group 2.ResultsThe median age of our patients was 70 (51–88) years. Eighty-eight patients (94.6%) were PSMA-positive, 78 patients (83.8%) were FDG-positive, and 89 patients (95.6%) were or PSMA or FDG positive. When the two groups were compared in terms of patient-based parameters, the median age and GS were found to be significantly higher in group 2. ROC analyses revealed that age and GS were significant in predicting group 2.ConclusionSince glucose metabolism can increase in CRPC patients with advanced age and high GS, we recommend combining [¹⁸F]FDG PET/CT with [⁶⁸Ga]Ga-PSMA PET/CT in routine clinical practice in order to identify this patient subset and refer them to additional therapies.     

Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)

Background

Inhibition of the epidermal growth factor receptor (EGFR) has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC). Somatic mutations of EGFR were found in lung adenocarcinoma that lead to exquisite dependency on EGFR signaling; thus patients with EGFR-mutant tumors are at high chance of response to EGFR inhibitors. However, imaging approaches affording early identification of tumor response in EGFR-dependent carcinomas have so far been lacking.

Methodology/Principal Findings

We performed a systematic comparison of 3′-Deoxy-3′-[¹⁸F]-fluoro-L-thymidine ([¹⁸F]FLT) and 2-[¹⁸F]-fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) positron emission tomography (PET) for their potential to identify response to EGFR inhibitors in a model of EGFR-dependent lung cancer early after treatment initiation. While erlotinib-sensitive tumors exhibited a striking and reproducible decrease in [¹⁸F]FLT uptake after only two days of treatment, [¹⁸F]FDG PET based imaging revealed no consistent reduction in tumor glucose uptake. In sensitive tumors, a decrease in [¹⁸F]FLT PET but not [¹⁸F]FDG PET uptake correlated with cell cycle arrest and induction of apoptosis. The reduction in [¹⁸F]FLT PET signal at day 2 translated into dramatic tumor shrinkage four days later. Furthermore, the specificity of our results is confirmed by the complete lack of [¹⁸F]FLT PET response of tumors expressing the T790M erlotinib resistance mutation of EGFR.

Conclusions

[¹⁸F]FLT PET enables robust identification of erlotinib response in EGFR-dependent tumors at a very early stage. [¹⁸F]FLT PET imaging may represent an appropriate method for early prediction of response to EGFR TKI treatment in patients with NSCLC.     

Effect of γ-radiation on the ratio of [18F]2-fluoro-2-deoxy-D-glucose to glucose utilization in human glioblastoma cellsin vitro

The glucose consumption in tumoursin vivo as reflected by uptake of [¹⁸F]2-fluoro-2-deoxy-D-glucose (¹⁸FDG) using positron emission tomography (PET) is currently under investigation as a measure of tumour response to radiotherapy. The calculation of cerebral metabolic rate of glucose from¹⁸FDG-PET data requires a proportionality factor referred to as the lumped constant. In the presentin vitro study, the utilizations of¹⁸FDG and glucose have been measured in a human glioblastoma cell line (86HG-39) as a function of γ-radiation dose with various post-irradiation times and of different fractionation modes. The ratio of utilization of¹⁸FDG to that of glucose (R_F/G), assumed to correspond to the lumped constant, was observed to increase 12 and 24 h after single fraction γ-exposure by factors ranging from 1.2 to 1.5 compared with the non-irradiated controls. It decreased after multiple fraction γ-exposure (4 × 2 Gy) by a factor of 0.7 compared with the single fraction schedule (1 × 8 Gy). The results suggest that the affinities of glucose transporters or hexokiriase enzyme or both for¹⁸FDG and glucose could be influenced by γ-irradiation in this tumour cell linein vitro. Apparent changes of the glucose consumption determined with PET in human tumours following radiotherapy may, therefore, not be solely due to changes in cellular metabolism or cell number but may also be due to changes in R _F/G .     

Apport d’un nouveau score visuel en TEP/TDM au 18Fluorodeoxyglucose (18FDG) lors des récidives ganglionnaires de cancer ORL après traitement initial

New visual score in PET/CT 18Fluorodeoxyglucose (¹⁸FDG) to evaluate lymph node recurrence of head and neck cancer after initial treatment. Neck dissection for node recurrence of head and neck cancer is known for important morbidity after initial radiation therapy. ¹⁸FDG PET/CT in this situation looks interesting but needs standardized interpretation. Our objective was to develop a PET/CT interpretation method in suspicious locoregional head and neck recurrence. Twenty-seven patients with suspicious lymph node recurrence after initial radiation ± chemotherapy for head and neck cancer were retrospectively included. ¹⁸FDG PET/CT was performed before neck dissection and histological data. Initial PET records, binary visual scale, five-point visual scale “Deauville like” and semi-quantitative index were assessed by 2 reviewers. A lymph node recurrence was confirmed in 19 patients (70%) based on histological results. PET records analysis found 6 false positive (FP), 2 true negative (TN) and 19 true positive (TP), with a sensibility (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of 100%, 25%, 76% and 100%, respectively. Binary visual scale reclassified 1/6 FP. “Deauville like” criteria, reclassified 4/6 FP with the first reviewer (P < 0.001) and 5/6 with the second (P < 0.002), improving Sp and PPV of 66% and 95%, respectively. Kappa concordance coefficient for “Deauville like” scale was 0.88. Semi-quantitative index like SUVmax, SUVmean, SUVpeak, MTV, TLG and SAM showed no statistical value. Those preliminary results warrant a standardized visual scale, particularly the “Deauville like” criteria for ¹⁸FDG PET/CT interpretation in suspected lymph node recurrence of head and neck cancer.     

Comparaison IRM de diffusion corps entier et TEP/TDM au 18FDG dans le diagnostic de myélome symptomatique

IntroductionOur work aims to compare whole-body diffusion MRI (DWMRI) and ¹⁸FDG PET/CT in the diagnosis of symptomatic myeloma.Patients and methodFrom November 2008 till May 2010, 19 patients were investigated by DWMRI and by ¹⁸FDG PET/CT. The patients were classified according to the criteria of the International Myeloma Working Group in eight non-symptomatic myelomas and 11 symptomatic myelomas. The sensitivity and the specificity of two methods of imaging were studied by retaining the presence or the absence of a diffuse infiltration (ID), focal lesions (FL), or both parameters (FL + ID), in both modalities of imaging. We compared the concordance between two techniques for every patient by using these signs using a weighted kappa test.ResultsThe performances of both modalities seem comparable, with superior diagnostic performances for the FL (Se = 100% and Sp = 75% in DWMRI and Se = 91% and Sp = 75% for ¹⁸FDG PET/CT). By combining both parameters, the ¹⁸FDG PET/CT seems more specific, but the sensitivity is comparable in both modalities (Se = 100% in MRI and Se = 100% in ¹⁸FDG PET/CT; Sp = 37% in DWMRI and Sp = 62% for ¹⁸FDG PET/CT). The concordance between both techniques is better by taking into account the FL than the other parameters (weighted kappa = 0.61 for FL, 0.5 for the FL + ID and 0.16 for ID alone).ConclusionDiagnostic performances of whole-body diffusion MRI and ¹⁸FDG PET/CT seem equivalent, but concordance between both techniques is imperfect. Further studies are necessary to understand this discrepancy.     

PET/CT Assessment of Response to Therapy: Tumor Change Measurement,Truth Data,and Error

We describe methods and issues that are relevant to the measurement of change in tumor uptake of ¹⁸F-fluorodeoxyglucose (FDG) or other radiotracers, as measured from positron emission tomography/computed tomography (PET/CT) images, and how this would relate to the establishment of PET/CT tumor imaging as a biomarker of patient response to therapy. The primary focus is on the uptake of FDG by lung tumors, but the approach can be applied to diseases other than lung cancer and to tracers other than FDG. The first issue addressed is the sources of bias and variance in the measurement of tumor uptake of FDG, and where there are still gaps in our knowledge. These are discussed in the context of measurement variation and how these would relate to the early detection of response to therapy. Some of the research efforts currently underway to identify the magnitude of some of these sources of error are described. In addition, we describe resources for these investigations that are being made available through the Reference Image Database for the Evaluation of Response project. Measures derived from PET image data that might be predictive of patient response as well as the additional issues that each of these metrics may encounter are described briefly. The relationship between individual patient response to therapy and utility for multicenter trials is discussed. We conclude with a discussion of moving from assessing measurement variation to the steps necessary to establish the efficacy of PET/CT imaging as a biomarker for response.     

Identification of Metabolic Biomarkers Using Serial 18F–FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer

PURPOSE. To evaluate the prognostic value of metabolic parameters derived from serial ¹⁸F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with advanced epithelial ovarian cancer (EOC). METHODS. Thirteen patients with advanced EOC who received surgical staging and adjuvant platinum-based combination chemotherapy were prospectively enrolled. ¹⁸F–FDG PET/CT was performed before and after the surgical staging, and after third cycle of chemotherapy. Tumor glucose metabolism at baseline and its change after operation and third cycle of chemotherapy such as changes of maximum standardized uptake values (ΔSUV_max) via ¹⁸F–FDG PET/CT were measured, and assessed regarding their ability to predict recurrence. RESULTS. Median duration of progression-free survival (PFS) was 25 months (range, 13–34), and although optimal debulking was performed in 10 patients, 5 (38.5%) patients experienced recurrence. Univariate analyses showed significant associations between recurrence and low ΔSUV_max after surgical staging, and low SUV_max change after third cycle of chemotherapy. Multivariate analysis identified low ΔSUV_max after third cycle of chemotherapy as an independent risk factor for recurrence (P = .047, hazard ratio (HR) 16.375, 95% CI 1.041–257.536). Kaplan–Meier survival curves showed that PFS significantly differed in groups categorized based on ΔSUV_max after chemotherapy (P = .001, log-rank test). CONCLUSIONS. ¹⁸F–FDG PET/CT allows for prediction of treatment response by the level of FDG uptake in terms of SUV at baseline and after chemotherapy. The metabolic response measured as ΔSUV_max after third cycle of chemotherapy appears to be promising predictor of recurrence in patients with advanced EOC.     

Clinical value of (18)F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma

Objective: To evaluate the clinical value of ¹⁸F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma. Methods: 66 postoperative patients with colorectal carcinoma underwent whole-body FDG PET/CT. The final histopathological and formal clinical follow-up findings were used as gold standard to determine the sensitivity and specificity of FDG PET/CT and enhanced CT of the same periods. Results: The sensitivity and specificity of FDG PET/CT in detecting recurrence are 96.30%, 94.87% (while enhanced CT are 70.37% and 87.18% respectively). The sensitivity and specificity in detecting metastasis are 95.35%, 82.61% (enhanced CT are 61.90%, 75.00%). SUVmax was significantly higher in malignant lesions [range 4.16–22.00, mean ± standard deviation (x ± s) 8.06 ± 4.30] than in benign ones (range1.18–6.25, x ± s 2.82 ± 1.02). Conclusion: At present, whole-body ¹⁸F-FDG PET/CT is an advanced diagnostic imaging technique in detecting loco-regional recurrence and metastasis in postoperative patients with colorectal carcinoma for its higher sensitivity and specificity.